Tufts Finds Cardiovascular Drug Approval Rate in the US Fell

Sep 12, 2017
By Applied Clinical Trials Editors

Tufts Center for the Study of Drug Development recently completed a study, which was released September 12. The findings show that even though the rate at which investigational drugs received marketing approval in the U.S. has declined in recent years,  the cardiovascular approval rate trailed other drug approvals, while the time needed to develop cardiovascular drugs rose. 

Read the full release here

lorem ipsum